In the methionine/choline-deficient diet (MCD) model, RSL-3 (a GPX4 inhibitor) aggravated liver steatosis, and inflammation in NASH, while deferoxamine mesylate nullified this effect through chelating iron. The gene discussed is GPX4; the disease is metabolic dysfunction-associated steatohepatitis.